PRP or autologous blood versus placebo
   withdrawal
      The withdrawal rates were: 3 out of 39 (8%) with placebo versus 1 out of 41 (2%) with PRP or autologous blood (RR 0.32, 95% CI 0.03 to 2.92, 7 studies).
   adverse events
      The adverse events rates were: 35 out of 208 (17%) with placebo versus 41 out of 217 (19%) with PRP or autologous blood (RR 1.14, 95% CI 0.76 to 1.72, 5 studies).
PRP or autologous blood versus corticosteroid injection
   adverse events
      The adverse events rates were: 24 out of 195 (12%) with corticosteroid injection versus 46 out of 201 (23%) with PRP or autologous blood (RR 1.64, 95% CI 0.65 to 4.12, 7 studies).
   withdrawal
      None of the studies measured this outcome.
PRP and dry needling versus dry needling alone
   adverse events
      The adverse events rates were: 1 out of 13 (8%) with dry needling alone versus 2 out of 15 (13%) with PRP and dry needling (RR 1.73, 95% CI 0.18 to 16.99, 1 study).
   withdrawal
      The withdrawal rates were: 1 out of 13 (8%) with dry needling alone versus 2 out of 15 (13%) with PRP and dry needling (RR 1.73, 95% CI 0.18 to 16.99, 1 study).
PRP versus autologous blood
   adverse events
      The adverse events rates were: 4 out of 14 (29%) with autologous blood versus 9 out of 14 (64%) with PRP (RR 2.25, 95% CI 0.9 to 5.62, 2 studies).
   withdrawal
      None of the studies measured this outcome.
Autologous blood versus ESWT
   adverse events
      The adverse events rates were: 12 out of 20 (60%) with ESWT versus 3 out of 20 (15%) with Autologous blood (RR 0.25, 95% CI 0.08 to 0.75, 1 study).
   withdrawal
      None of the studies measured this outcome.
PRP versus arthroscopic surgery
   withdrawal
      None of the studies measured this outcome.
   adverse events
      None of the studies measured this outcome.
Autologous blood plus bandage and exercise versus bandage and exercise
   withdrawal
      None of the studies measured this outcome.
   adverse events
      None of the studies measured this outcome.
PRP versus laser applications
   adverse events
      The adverse events rates were: 0 out of 29 (0%) with laser applications versus 0 out of 27 (0%) with PRP (RR 0.0, 95% CI -0.07 to 0.07, 1 study).
   withdrawal
      None of the studies measured this outcome.
Autologous blood versus polidocanol injection
   withdrawal
      None of the studies measured this outcome.
   adverse events
      None of the studies measured this outcome.
PRP vs physical therapy
   withdrawal
      None of the studies measured this outcome.
   adverse events
      None of the studies measured this outcome.
Subgroups PRP and blood versus corticosteroid at 3 months
   withdrawal
      None of the studies measured this outcome.
   adverse events
      None of the studies measured this outcome.
Subgroup leucocyte rich versus leucocyte poor PRP at 3 months
   adverse events
      The adverse events rates were: 35 out of 208 (17%) with leucocyte poor PRP at 3 months versus 41 out of 217 (19%) with Subgroup leucocyte rich (RR 1.14, 95% CI 0.76 to 1.72, 3 studies).
      10 out of 74 (14%) with leucocyte poor PRP at 3 months versus 12 out of 81 (15%) with Subgroup leucocyte rich (RR 1.15, 95% CI 0.53 to 2.51, 3 studies) at Leucocyte poor. 
   withdrawal
      None of the studies measured this outcome.
PRP or autologous blood versus steroid injection using MD
   withdrawal
      None of the studies measured this outcome.
   adverse events
      None of the studies measured this outcome.
